Denne siden fornyes snart!

Live | Norge | Sverige | Danmark | Europa | USA | Valuta | Råvarer | Gråmarked | Fond | NDXForsinkede kurser. Sist oppdatert: lørdag 22. september 
Største handler

10/11-2017 11:50:23: (BIOPOR.CPH) USPTO approves BioPorto.s NGAL Trauma patent for issuance

isted on the 
Nasdaq Copenhagen stock exchange.r issuance in the US after a long period 
of waiting for issuance of new diagnostic patens in the US. Along with the 
other patents in our IP portfolio it ensures our coverage and we maintain our 
position as a major player in the NGAL market..  
For further information, please contact: 
Gry Husby Larsen, General Counsel 
Peter M. Eriksen, CEO 
Telephone +45 4529 0000, e-mail 
About BioPorto 
BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides 
healthcare professionals in clinical and research settings a range of 
diagnostic tests and antibodies. Our pioneering product portfolio includes 
assays for underserved disease states such as NGAL for acute kidney injury. 
BioPorto has its headquarters in Copenhagen, Denmark and is lBioPorto  A/S
Inside information

USPTO approves BioPorto.s NGAL Trauma patent for issuance

United States Patent and Trademark Office (USPTO) has announced, that 
BioPorto's NGAL Trauma patent, specifically relating to diagnosing and treating 
radiation injury, has been approved for issuance.  
BioPortos. issued patents in the US now comprises BioPorto.s NGAL Ratio patent 
and issued NGAL patent in-licensed from The Trustees of Columbia University. In 
addition to the issued NGAL patents BioPorto has a number pending NGAL patent 
applications in the US. Please see BioPorto.s Annual Report for a description 
of all BioPorto.s issued patents and applications.  
Peter Mørch Eriksen, CEO of BioPorto, comments: "We are very pleased that the 
NGAL Trauma patent is now approved fo

Ekstern link:
Ekstern link:

Nyheten er levert av OMX.

Utforming |  Hjelp |  Personvern  | Bytt til sanntid Ingen åpne markeder
lørdag 22/09-2018 22:34:51